The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.

Journal Article (Journal Article)

CAR T-cell therapy is well tolerated and effective in patients with Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). However, even second- generation anti-CD30 CAR T-cells with CD28 (28z) costimulatory domains failed to achieve the desired rate of complete responses. In the present study, we developed second-generation (CD28z) and third-generation (CD28BBz) CAR T-cells targeting CD30 and investigated their efficacy in vitro and in vivo. Both of CD28z and CD28BBz anti-CD30 CAR T cells were similar regarding amplification, T cell subsets distribution, T cell activity, effector/memory and exhaustion. However, we found that the 28BBz anti-CD30 CAR T-cells persist long-term, specifically homing to the tumor and mediating powerful antitumor activity in tumor xenograft models. Subsequently, we also demonstrated that the third generation anti-CD30 CAR T-cells have miner side effects or potential risks of tumorigenesis. Thus, anti-CD30 CAR T-cells represent a safe and effective treatment for Hodgkin lymphoma.

Full Text

Duke Authors

Cited Authors

  • Zhang, S; Gu, C; Huang, L; Wu, H; Shi, J; Zhang, Z; Zhou, Y; Zhou, J; Gao, Y; Liu, J; Leng, Y; Liu, X; Zhang, Q; Huang, L; Tong, X; Young, KH; Li, J; Zhu, H; Zhang, T

Published Date

  • June 21, 2022

Published In

Volume / Issue

  • 12 / 1

Start / End Page

  • 10488 -

PubMed ID

  • 35729339

Pubmed Central ID

  • PMC9213494

Electronic International Standard Serial Number (EISSN)

  • 2045-2322

Digital Object Identifier (DOI)

  • 10.1038/s41598-022-14523-0


  • eng

Conference Location

  • England